4:15 PM - 4:30 PM (PDT), Monday, June 13, 2022
NIBEC is established as a spin-off venture from Seoul National University, South Korea at 2004 and listed in Korean Stock Market (KOSDAQ) at 2011. The company's main technology is based on target oriented peptide therapeutic discovery (TOPscovery) platform for drug discovery and development. The company’s focus of therapeutic area includes fibrosis, IBD and oncology with well-defined mode of action. In addition to the therapeutic peptide asset, NIBEC has drug delivery platforms; 1) target tissue/cell penetrating peptide carrier (for example, BBB shuttle, liver, lung, immune cell, cancer targeting etc) and 2) oral peptide/protein delivery formulation. In addition to the drug development, the company holds medical device manufacturer license for tissue engineering biomaterials, tissue regenerative therapy dedicated to bone healing. The company has two research institutes and one manufacturing facility with fully granted GMPs for both drug and medical device.
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Korea - South Korea
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Protein and peptide
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):